Diflomotecan (BN80915) Administered Once Every 3 Weeks in Treating Patients With Sensitive Small Cell Lung Cancer (SCLC)
Status:
Completed
Trial end date:
2005-02-01
Target enrollment:
Participant gender:
Summary
This is a Phase II, open-label, multicenter, single-arm, exploratory "proof of concept"
study. Diflomotecan (7 mg fixed dose) will be administered as a 20-minute IV infusion once
every 3 weeks in patients with sensitive small cell lung cancer (SCLC) with progressive
disease after first-line treatment with a platinum-based regimen.